You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

128 Results
Guidelines and Advice
Status: Current
ID: GL 4-11
Version: 2
Updated
Mar 2026
Guidelines and Advice
Status: Current
ID: GL 6-A-2023-1
Version: 2
Updated
Jan 2026
Guidelines and Advice
Status: Archived
ID: 14-3
Jul 2005
Guidelines and Advice
Status: Archived
ID: 13-7
Feb 2005
Guidelines and Advice
Status: Archived
ID: CED 1
Jun 2005
Guidelines and Advice
Status: Archived
ID: 12-4
Apr 2005
Guidelines and Advice
Status: Archived
ID: 2-20-2
Sep 2005
Guidelines and Advice
Status: Current
ID: GL 8-12
Updated
Jan 2026
Guidelines and Advice
Status: Current
ID: 19-4
Version: 2
Updated
Mar 2026
Guidelines and Advice
Status: Current
ID: PET 2024-2
Updated
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma
High Cost Therapy Funding Program
    Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
teclistamab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
elranatamab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026

Pages